Cardiovascular disease (CVD) remains the leading cause of death worldwide and is a major driver of critical illness, resulting in admission to cardiac intensive care units (CICUs). Patients with acute, life-threatening CVD often experience episodes of acute decompensation characterized by high symptom burden that may p...
A. Song, S. Feder, Omar Elmadhoun et al.· Journal of Palliative Medici...· 0 citations
Treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications, and these findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population.
Konstantinos D. Rizas, K. Mourouzis, D. Rath et al.· Nature Medicine· 3 citations
In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year.
G. Montalescot, E. Ferrari, G. Souteyrand et al.· Journal of the American Medi...· 3 citations
In this analysis including a large cohort of post-myocardial infarction patients with reduced LVEF, the estimated mortality reduction associated with primary prevention ICD implantation progressively decreased over time.
Alireza Sepehri Shamloo, T. Chiba, J. G. Tijssen et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
